TO INNOVATIONS

ORAL ABSTRACT SESSIONS FRIDAY 28 OCTOBER 2016
15.55 [OA-425-28]
The effect of risk factor control on tuberculosis in Taiwan: a modelling study
C-H Wang, H-H Lin (Taiwan)
16.05 [OA-426-28]
Challenges in diagnosing diabetes among those with newly diagnosed pulmonary TB: diagnostic variability
according to diabetes disease severity
D Grint, A Riza, C Ugarte-Gil, K Ronacher, B Alisjahbana, H Dockrell, R van Crevel, J Critchley, on behalf of the TANDEM Consortium
(United Kingdom, Romania, Peru, South Africa, Indonesia, Netherlands)
16.15 [OA-427-28]
A rapid assessment of the nutritional status of TB patients and the integration of a nutrition assistance programme in Ethiopia
J Ahmed, A Kassa, M H/silassie, A Fantaye (Ethiopia)
16.25 [OA-428-28]
Alcohol and substance use among participants in a clinical trial receiving home-based DOT for tuberculosis
C Pinedo, J Jimenez, K Tintaya, S R Leon, J M Coit, M B Milstein, L Lecca, C D Mitnick (Peru, United States of America)
ORAL ABSTRACT SESSION 19 3 15:15-16:45 3 SESSION ROOM 12
DRUGS FOR MRD-TB: CHALLENGES AND SUCCESSES
Co-chairs: Francesca Conradie (South Africa), ID Rusen (Canada) – Section: Tuberculosis
15.15 [OA-429-28]
Timing of acquired resistance to fluoroquinolones and second-line injectable drugs during treatment of MDR-TB
P Cegielski, C Contreras, T Dalton, V Leimane, K Kliiman, H J Kim, M van der Walt, T Tupasi, O Demikhova, L Via, C Kvasnovsky, L Diem,
M Yagui, J Bayona, Preserving Effective TB Treatment Study (PETTS) (United States of America, Peru, Latvia, Estonia, Korea, Republic of,
South Africa, Philippines, Russian Federation)
15.25 [OA-430-28]
Comparable 12-month incidence of renal insufficiency in MDR-TB patients treated with standard kanamycin-based regimens or concomitantly
with tenofovir in Namibia
E Sagwa, N Ruswa, F Mavhunga, T Rennie, A Mengistu, A K Mantel-Teeuwisse (Netherlands, Namibia)
15.35 [OA-431-28]
Dose-ranging activity of clofazimine in combination with the first-line regimen in the mouse model of tuberculosis treatment
N Ammerman, R Swanson, E Bautista, H Guo, D Almeida, E Nuermberger, J Grosset (United States of America, South Africa)
15.45 [OA-432-28]
Roll-out of new drugs to treat DR-TB: success and challenges with implementation
N Misra, I Master (South Africa)
15.55 [OA-433-28]
Treatment outcome in patients with multidrug-resistant tuberculosis as measured by sputum culture conversion rate in Rwanda
M C Muvunyi, J C S Ngabonziza, Y Mucyo, G Mutembayire, P Migambi, M Gasana (Rwanda)
16.05 [OA-434-28]
Predictors of unfavourable treatment outcome in adults with multidrug-resistant tuberculosis in India
D Nair, B Velayutham, K Thiruvengadam, J P Tripathy, A D Harries, K S Sachdeva, M Natrajan, S Swaminathan (India, France)
16.15 [OA-435-28]
DR-TB treatment costs: trends towards more affordability under threat with new drugs
C Perrin, W Bellamy, G Brigden, S Cloez (France, United States of America, Switzerland)
16.25 [OA-436-28]
High rates of ocular toxicity associated with ethambutol in the treatment of multidrug-resistant tuberculosis in South Africa
K N Nelson, N R Gandhi, N S Shah, S Allana, A Campbell, K Mlisana, J C M Brust (United States of America, South Africa)
126 CONFRONTING RESISTANCE: FUNDAMENTALS TO INNOVATION - THE 47 TH UNION WORLD CONFERENCE ON LUNG HEALTH